{"id":324135,"date":"2026-03-26T00:00:00","date_gmt":"2026-03-26T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0011-2024-biopharma-ovarian-cancer-landscape-forecast-disease-landscape-forecast-g7\/"},"modified":"2026-04-25T11:14:12","modified_gmt":"2026-04-25T11:14:12","slug":"dlsfon0011-2026-biopharma-ovarian-cancer-landscape-forecast-disease-landscape-forecast-g7","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0011-2026-biopharma-ovarian-cancer-landscape-forecast-disease-landscape-forecast-g7\/","title":{"rendered":"Ovarian Cancer &#8211; Landscape &#038; Forecast &#8211; Disease Landscape &#038; Forecast (G7)"},"content":{"rendered":"<p>The treatment landscape for ovarian cancer has been revolutionized by the angiogenesis inhibitor bevacizumab and the <abbr data-abbreviation-entity=\"5349\" title=\"poly ADP (adenosine diphosphate)-ribose polymerase\">PARP<\/abbr> inhibitors olaparib (Lynparza; AstraZeneca \/ Merck &#038; Co.), niraparib (Zejula; GSK), and rucaparib (Rubraca; Pharma&#038;), which provide therapeutic options for ovarian cancer patients, including those with <abbr data-abbreviation-entity=\"8121\" title=\"homologous recombination deficiency\">HRD<\/abbr> and deleterious <abbr data-abbreviation-entity=\"7699\" title=\"breast cancer gene\">BRCA<\/abbr> mutations. The folate receptor-alpha (FR\u03b1) protein is now a target in the treatment of advanced disease; mirvetuximab soravtansine (Elahere; ImmunoGen \/ AbbVie) entered the U.S. and European markets as the first <abbr data-abbreviation-entity=\"5275\" title=\"antibody drug conjugate\">ADC<\/abbr> targeting patients with high <abbr data-abbreviation-entity=\"5341\" title=\"folate receptor alpha\">FR\u03b1<\/abbr>-expressing tumors (<abbr data-abbreviation-entity=\"7657\" title=\"Tumor Proportion Score\">TPS<\/abbr> \u2265 75%). The late-phase pipeline for ovarian cancer is rapidly evolving. Novel drugs with distinct mechanisms of action, including immune checkpoint inhibitors and <abbr data-abbreviation-entity=\"5275\" title=\"antibody drug conjugate\">ADC<\/abbr>s, could further diversify treatment options if successful in late-phase studies.<\/p>\n<p><b>Questions answered<\/b><\/p>\n<ul class=\"round-bullets\">\n<li>What is the size of clinically and commercially relevant drug-treatable ovarian cancer populations, and how will drug-treatment rates change (if at all) over time?<\/li>\n<li>What is the current treatment landscape for ovarian cancer? What are interviewed experts\u2019 opinions on current therapies?<\/li>\n<li>What are the most promising agents in the late-phase pipeline, and how will they shape the future of the ovarian cancer market?<\/li>\n<li>What are the main drivers of, and constraints in, the treatment of ovarian cancer, and how will this market evolve over the forecast period?<\/li>\n<\/ul>\n<p><strong>Geography:<\/strong> United States, <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>, Japan<\/p>\n<p><strong>Primary research:<\/strong> Country-specific interviews with thought-leading medical oncologists. Survey data collected for this and other Clarivate research<\/p>\n<p><strong>Epidemiology:<\/strong> Diagnosed incidence by country and disease stage; clinically and market-relevant drug-treatable populations<\/p>\n<p><strong>Forecast:<\/strong> 10-year, annualized, drug-level sales and patient share of key ovarian cancer therapies through 2034, segmented by brands \/ generics and epidemiological subpopulations<\/p>\n<p><strong>Drug treatments:<\/strong> Coverage of key current and late-phase emerging therapies<\/p>\n<p><b>Product description<\/b><\/p>\n<p>Disease Landscape &#038; Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<ul class=\"BulletListStyle1 SCXW200847613 BCX0 round-bullets\">\n<li>Optimize your long-term disease and development strategy.<\/li>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<li>Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.<\/li>\n<li>Gauge the commercial outlook and impact of key market events.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-324135","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-ovarian-cancer","biopharma-therapy-areas-solid-tumors","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/324135","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":8,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/324135\/revisions"}],"predecessor-version":[{"id":575232,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/324135\/revisions\/575232"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=324135"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}